trending Market Intelligence /marketintelligence/en/news-insights/trending/FLeH0-w8o2IVjLjEvBGm9Q2 content esgSubNav
In This List

Acceleron prices common stock offering to raise $230M

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


Acceleron prices common stock offering to raise $230M

Acceleron Pharma Inc. priced an underwritten public offering of its common shares at $43 apiece.

The Cambridge, Mass.-based biopharmaceutical company will sell 5,348,838 common shares to raise $230 million in gross proceeds. It has also granted the underwriters an option to buy up to an additional 802,325 shares.

Acceleron, which develops therapeutics to treat serious and rare diseases, expects to receive about $215.8 million in net proceeds, which will fund the development of its drug candidates and future development programs. The funds will also be used for general and administrative expenses, as well as capital expenditures, working capital and other general corporate purposes.

The offering is expected to close Jan. 18.

Citigroup, J.P. Morgan and SVB Leerink are acting as joint book-running managers for the offering, with UBS Investment Bank as lead manager.